> Shares of Acorda Therapeutics took a big bounce yesterday when the company announced new data demonstrating that its multiple sclerosis drug Fampridine-SR does not raise heart-related risks higher than a placebo. Release
> Endo Pharmaceuticals CEO Peter Lankau has handed in his walking papers. Endo says he is leaving March 1 and will be replaced by its COO and CFO on an interim basis. Release
> BioSante Pharmaceuticals has reached agreement with the FDA on a special protocol assessment for its Phase III trials for LibiGel--a therapy for female sexual dysfunction. Report
> Following a recommendation from the FDA, NPS Pharmaceuticals is preparing a confirmatory late-stage study of Gattex in patients with short bowel syndrome. Report
> Shares of Medarex were buoyed yesterday by an analyst's remark that its cancer drug--ipilimumab--which delivered disappointing data in December, may yet demonstrate its ability to improve overall survival rates. Report
> Amsterdam-based Pharming says it expects a final EMEA decision on Rhucin in the second quarter and is close to detailing its request that the EMEA reexamine its application to market Rhucin in Europe. Report
> The FDA issued a warning letter to Replidyne regarding antibiotic faropenem medoxomil 300 mg. Letter
> Pipex Pharmaceuticals announced that its New Drug Application for oral tetrathiomolybdate has not been accepted by the FDA for further review as submitted. Release
> As if questions about the effectiveness of cholesterol meds weren't enough, now research is casting blood pressure remedies into doubt. Report
> Workers at Pfizer's Terre Haute, Indiana, plant where the ill-fated Exubera was made are, shall we say, less than exuberant today. The company has decided to cut 660 jobs there. Report
And Finally... Here's a troubling milestone: Bird flu deaths in Indonesia have hit 100. Report